Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MR Vaccine in Young Adults
NCT02196285Phase 1Completed
- Sponsor
- Immunobiological Technology Institute
- Start
- Sep 2015
- Primary completion
- Dec 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of measles vaccine, live attenuated + rubella vaccine, live attenuated in measles and rubella, sponsored by Immunobiological Technology Institute. Primary endpoint: Safety and tolerability analysis of the study vaccine at 9 months. Started Sep 2015; status: completed.
02
Drugs
measles vaccine, live attenuated + rubella vaccine, live attenuated
03
Conditions
measlesrubella
Beyond the preview
Go deeper on NCT02196285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02196285.